Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

85.7%

-0.8% vs industry average

Late-Stage Pipeline

43%

3 trials in Phase 3/4

Results Transparency

17%

1 of 6 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 3
3(75.0%)
Phase 2
1(25.0%)
4Total
Phase 3(3)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT02546154Completed

Time to Relapse of Iron Deficiency Anaemia After Standard Treatment With The Intravenous Iron (Monofer®)

Role: collaborator

NCT02130063Phase 3Completed

IDA-01 A Randomised, Open-Label, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) and Iron Sucrose

Role: collaborator

NCT02301026Completed

A Non-interventional Study of Diafer in Subjects With CKD on Haemodialysis for Treatment of Iron Deficiency

Role: collaborator

NCT01900197Completed

Time to Relapse of Iron Deficiency Anemia After Standard Treatment With a New Intravenous Iron (Monofer®)

Role: collaborator

NCT01895205Phase 3Completed

Treatment of Women After Severe Postpartum Haemorrhage

Role: collaborator

NCT02484768Phase 2Withdrawn

IV Iron Treatment of Restless Legs Syndrome

Role: collaborator

NCT01895218Phase 3Completed

Treatment of Women After Postpartum Haemorrhage

Role: collaborator

All 7 trials loaded